H.C. Wainwright analyst Ed Arce lowered the firm’s price target on Unicycive Therapeutics to $4.50 from $7 and keeps a Buy rating on the shares post the Q2 report. The reduced price target factors in equity dilution.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on UNCY:
- Unicycive Announces Second Quarter 2023 Financial Results and Provides Business Update
- Unicycive Therapeutics reports Q2 EPS (29c), consensus (34c)
- Unicycive Therapeutics to Participate in the H.C. Wainwright 2nd Annual Kidney Conference
- Unicycive announces publication of results on oxylanthanum carbonate
- Unicycive Therapeutics Announces Publication of Positive Comparison of Oxylanthanum Carbonate to Commercially Available Phosphate Binders in the American Journal of Nephrology